Eleftherios Michailidis

List of Publications by Year
in descending order

51 papers	10,746 citations	159525 30 h-index	189801 50 g-index
64 all docs	64 docs citations	64 times ranked	20015 citing authors

#	Article	IF	Citations
1	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	3.3	110
2	HIV nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2022, 240, 114554.	2.6	19
3	Enhanced SARS-CoV-2 neutralization by dimeric IgA. Science Translational Medicine, 2021, 13, .	5.8	379
4	Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. Cell, 2021, 184, 120-132.e14.	13.5	328
5	Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. Journal of Experimental Medicine, 2021, 218, .	4.2	130
6	Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. Cell Host and Microbe, 2021, 29, 267-280.e5.	5.1	127
7	Primary human hepatocyte gene editing: Prometheusâ€™ chains are loosening. Molecular Therapy, 2021, 29, 1666-1667.	3.7	0
8	DRUL for school: Opening Pre-K with safe, simple, sensitive saliva testing for SARS-CoV-2. PLoS ONE, 2021, 16, e0252949.	1.1	5
9	Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient-Derived Xenografts and Direct-from-Patient Screening. Cancer Discovery, 2021, 11, 2544-2563.	7.7	27
10	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	5.6	357
11	Development of Human Immunodeficiency Virus Type 1 Resistance to 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2021, 65, e0116721.	1.4	10
12	Replication and single-cycle delivery of SARS-CoV-2 replicons. Science, 2021, 374, 1099-1106.	6.0	49
13	RNR-R2 Upregulation by a Short Non-Coding Viral Transcript. Biomolecules, 2021, 11, 1822.	1.8	1
14	Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice. Molecular Therapy - Methods and Clinical Development, 2020, 18, 189-198.	1.8	19
15	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	13.7	1,742
16	LY6E impairs coronavirus fusion and confers immune control of viral disease. Nature Microbiology, 2020, 5, 1330-1339.	5.9	170
17	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. Journal of Experimental Medicine, 2020, 217, .	4.2	503
18	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,749

#	Article	IF	Citations
19	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,983
20	Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice. Science Advances, 2020, 6, .	4.7	23
21	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. Cell Host and Microbe, 2020, 28, 335-349.e6.	5.1	48
22	Expansion, in vivoâ€“ex vivo cycling, and genetic manipulation of primary human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1678-1688.	3.3	41
23	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. ELife, 2020, 9, .	2.8	1,239
24	Inherited IL-18BP deficiency in human fulminant viral hepatitis. Journal of Experimental Medicine, 2019, 216, 1777-1790.	4.2	70
25	Characterization of Novel Splice Variants of Zinc Finger Antiviral Protein (ZAP). Journal of Virology, 2019, 93, .	1.5	61
26	Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus. Viruses, 2019, 11, 1039.	1.5	14
27	3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	19
28	A robust cell culture system supporting the complete life cycle of hepatitis B virus. Scientific Reports, 2017, 7, 16616.	1.6	61
29	Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. Journal of Hepatology, 2017, 66, 288-296.	1.8	65
30	Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells. Journal of Hepatology, 2016, 65, 334-343.	1.8	73
31	Structural basis of HIV inhibition by translocation-defective RT inhibitor 4â€²-ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA). Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9274-9279.	3.3	73
32	Mopping up miRNA: An integrated HBV transcript disrupts liver homeostasis by sequestering miR-122. Journal of Hepatology, 2016, 64, 257-259.	1.8	9
33	CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Scientific Reports, 2015, 5, 10833.	1.6	245
34	Hepatitis B virus induces RNR-R2 expression via DNA damage response activation. Journal of Hepatology, 2015, 63, 789-796.	1.8	30
35	Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach. Antimicrobial Agents and Chemotherapy, 2015, 59, 3482-3492.	1.4	20
36	SAMHD1 Has Differential Impact on the Efficacies of HIV Nucleoside Reverse Transcriptase Inhibitors. Antimicrobial Agents and Chemotherapy, 2014, 58, 4915-4919.	1.4	25

#	Article	IF	Citations
37	4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms. Journal of Biological Chemistry, 2014, 289, 24533-24548.	1.6	80
38	Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. Retrovirology, 2013, 10, 65.	0.9	36
39	Effects of Substitutions at the 4â€² and 2 Positions on the Bioactivity of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine. Antimicrobial Agents and Chemotherapy, 2013, 57, 6254-6264.	1.4	35
40	The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes. PLoS Pathogens, 2013, 9, e1003125.	2.1	96
41	Evaluation of Combinations of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine with Clinically Used Antiretroviral Drugs. Antimicrobial Agents and Chemotherapy, 2013, 57, 4554-4558.	1.4	21
42	Biochemical Mechanism of HIV-1 Resistance to Rilpivirine. Journal of Biological Chemistry, 2012, 287, 38110-38123.	1.6	59
43	HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors. Journal of Biological Chemistry, 2012, 287, 29988-29999.	1.6	9
44	Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. Nucleic Acids Research, 2012, 40, 345-359.	6.5	14
45	Antiviral therapies: Focus on hepatitis B reverse transcriptase. International Journal of Biochemistry and Cell Biology, 2012, 44, 1060-1071.	1.2	40
46	Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase. Antimicrobial Agents and Chemotherapy, 2012, 56, 2048-2061.	1.4	31
47	K70Q Adds High-Level Tenofovir Resistance to â€œQ151M Complexâ€•HIV Reverse Transcriptase through the Enhanced Discrimination Mechanism. PLoS ONE, 2011, 6, e16242.	1.1	29
48	Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots. International Journal of Current Chemistry, 2011, 2, 253-260.	1.0	2
49	Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. Viruses, 2010, 2, 606-638.	1.5	70
50	Inhibitors of Foot and Mouth Disease Virus Targeting a Novel Pocket of the RNA-Dependent RNA Polymerase. PLoS ONE, 2010, 5, e15049.	1.1	21
51	Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor. Journal of Biological Chemistry, 2009, 284, 35681-35691.	1.6	117